Report LibraryAll Reports
Datamonitor Healthcare CV&Met Disease Analysis: Osteoporosis
December 23, 2021
With first-line bisphosphonates largely genericized, Prolia has been an important growth driver in the osteoporosis market, with flexible positioning as an alternative initial therapy for postmenopausal women with osteoporosis who are at high risk for osteoporotic fractures or do not tolerate bisphosphonates, or as an indefinite follow-on option after completion of anabolic therapy. Growth appeared to plateau in 2020, but that may have been due to the COVID-19 pandemic, as it appears to be picking up again in 2021. However, patent expirations in the US and other major markets in 2025 will open the door to biosimilars.
In the anabolic segment, the value of the class has been impacted by Forteo’s loss of exclusivity in 2019 and the arrival of two cheaper anabolic therapies, Tymlos in the US and Evenity. Dynamics have been somewhat different according to geography. In the US, despite an initial decline in 2018, with the subsequent growth of Tymlos and Evenity, as well as limited penetration of the biosimilar Bonsity, sales of the segment have been modestly increasing. Outside the US, where there has been more biosimilar competition and Tymlos is awaiting approval/launch in major markets, sales of the branded segment started to decrease after 2019.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Osteoporosis / Osteopenia|